[ { "@graph" : [ { "@id" : "http://purl.org/np/RAv5QNF3StOeRc1br3IL7SMsr4NMEyfmQ8DX7OzY6wAEY", "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ], "http://www.nanopub.org/nschema#hasAssertion" : [ { "@id" : "http://purl.org/np/RAv5QNF3StOeRc1br3IL7SMsr4NMEyfmQ8DX7OzY6wAEY#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance" : [ { "@id" : "http://purl.org/np/RAv5QNF3StOeRc1br3IL7SMsr4NMEyfmQ8DX7OzY6wAEY#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo" : [ { "@id" : "http://purl.org/np/RAv5QNF3StOeRc1br3IL7SMsr4NMEyfmQ8DX7OzY6wAEY#pubinfo" } ] } ], "@id" : "http://purl.org/np/RAv5QNF3StOeRc1br3IL7SMsr4NMEyfmQ8DX7OzY6wAEY#Head" }, { "@graph" : [ { "@id" : "http://purl.obolibrary.org/obo/DOID_409", "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Disease" } ] }, { "@id" : "http://purl.org/np/RAv5QNF3StOeRc1br3IL7SMsr4NMEyfmQ8DX7OzY6wAEY#association", "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ { "@id" : "http://purl.obolibrary.org/obo/DOID_409" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ { "@id" : "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ { "@id" : "https://identifiers.org/drugbank:DB01026" } ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "\"Coadministration of a number of CYP3A4 substrates such as dofetilide, quinidine cisapride and pimozide is contraindicated with ketoconazole tablets. Coadministration with ketoconazole can cause elevated plasma concentrations of these drugs and may increase or prolong both therapeutic and adverse effects to such an extent that a potentially serious adverse reaction may occur. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and sometimes resulting in life-threatening ventricular tachyarrhythmias including occurrences of torsades de pointes, a potentially fatal arrhythmia. (See PRECAUTIONS: Drug Interactions Additionally, the following other drugs are contraindicated with ketoconazole tablets: methadone, disopyramide, dronedarone, ergot alkaloids such as dihydroergotamine, ergometrine, ergotamine, methylergometrine, irinotecan, lurasidone, oral midazolam, alprazolam, triazolam, felodipine, nisoldipine, ranolazine, tolvaptan, eplerenone, lovastatin, simvastatin and colchicine. (See PRECAUTIONS: Drug Interactions Coadministration of ketoconazole tablets with oral midazolam, oral triazolam or alprazolam has resulted in elevated plasma concentrations of these drugs. This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. Concomitant administration of ketoconazole tablets with oral triazolam, oral midazolam or alprazolam is contraindicated. (See PRECAUTIONS: Drug Interactions Coadministration of CYP3A4 metabolized HMG-CoA reductase inhibitors such as simvastatin, and lovastatin is contraindicated with ketoconazole tablets. (See PRECAUTIONS: Drug Interactions Concomitant administration of ergot alkaloids such as dihydroergotamine and ergotamine with ketoconazole tablets is contraindicated. (See PRECAUTIONS: Drug Interactions The use of ketoconazole tablets is contraindicated in patients with acute or chronic liver disease. Ketoconazole tablets USP, 200 mg is contraindicated in patients who have shown hypersensitivity to the drug.\"" } ], "https://w3id.org/biolink/vocab/provided_by" : [ { "@id" : "https://w3id.org/um/NeuroDKG" } ], "https://w3id.org/biolink/vocab/relation" : [ { "@id" : "https://schema.org/MedicalContraindication" } ] }, { "@id" : "https://identifiers.org/drugbank:DB01026", "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Drug" } ] } ], "@id" : "http://purl.org/np/RAv5QNF3StOeRc1br3IL7SMsr4NMEyfmQ8DX7OzY6wAEY#assertion" }, { "@graph" : [ { "@id" : "http://purl.org/np/RAv5QNF3StOeRc1br3IL7SMsr4NMEyfmQ8DX7OzY6wAEY#assertion", "http://www.w3.org/ns/prov#wasAttributedTo" : [ { "@id" : "https://orcid.org/0000-0002-1468-3557" } ] } ], "@id" : "http://purl.org/np/RAv5QNF3StOeRc1br3IL7SMsr4NMEyfmQ8DX7OzY6wAEY#provenance" }, { "@graph" : [ { "@id" : "http://purl.org/np/RAv5QNF3StOeRc1br3IL7SMsr4NMEyfmQ8DX7OzY6wAEY", "http://purl.org/dc/terms/created" : [ { "@type" : "http://www.w3.org/2001/XMLSchema#dateTime", "@value" : "2021-08-23T17:57:42.819+02:00" } ], "http://purl.org/dc/terms/creator" : [ { "@id" : "https://orcid.org/0000-0002-1468-3557" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ { "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ { "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ { "@id" : "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY" } ] }, { "@id" : "http://purl.org/np/RAv5QNF3StOeRc1br3IL7SMsr4NMEyfmQ8DX7OzY6wAEY#sig", "http://purl.org/nanopub/x/hasAlgorithm" : [ { "@value" : "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey" : [ { "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature" : [ { "@value" : "Uooc/T1XFgjABgRj+kqoZraGPipUSF8UqKDLk8I8XTCrCDolxaVaGTlJGHKTlqiblCR51KkQuWnQYySAKCU5e0LJ+OM+5JoXAlDnIlWIGJe46SBMHXFGyet6OlNVs64baiqUE1/Z2TxCBIDF0g6eVHfTLKVHrJZHB66Usbhu1Mc=" } ], "http://purl.org/nanopub/x/hasSignatureTarget" : [ { "@id" : "http://purl.org/np/RAv5QNF3StOeRc1br3IL7SMsr4NMEyfmQ8DX7OzY6wAEY" } ] } ], "@id" : "http://purl.org/np/RAv5QNF3StOeRc1br3IL7SMsr4NMEyfmQ8DX7OzY6wAEY#pubinfo" } ]